Department of Ophthalmology, Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia.
Department of Ophthalmology, Royal Adelaide Hospital, University of Adelaide, Adelaide, South Australia, Australia.
Clin Exp Ophthalmol. 2019 Jul;47(5):598-604. doi: 10.1111/ceo.13466. Epub 2019 Feb 20.
Five-year survival rates in patients undergoing vitrectomy for diabetic retinopathy (DR) vary from 68% to 95%. No study has been conducted in an Australian population.
We aimed to determine the survival rates of patients undergoing diabetic vitrectomy in an Australian population.
Retrospective audit, tertiary centre hospitals and private practices.
All individuals in South Australia and the Northern Territory who underwent their first vitrectomy for diabetic complications between January 1, 2007 and December 31, 2011.
An audit of all eligible participants has been completed previously. Survival status as of July 6, 2018 and cause of death were obtained using SA/NT DataLink. Kaplan-Meier survival curves and multivariate cox-regressions were used to analyse survival rates and identify risk factors for mortality.
Five-, seven- and nine-year survival rates.
The 5-, 7- and 9-year survival rates were 84.4%, 77.9% and 74.7%, respectively. The most common cause of death was cardiovascular disease. Associated with increased mortality independent of age were Indigenous ethnicity (HR = 2.04, 95% confidence interval [CI]: 1.17-3.57, P = 0.012), chronic renal failure (HR = 1.76, 95% CI: 1.07-2.89, P = 0.026) and renal failure requiring dialysis (HR = 2.32, 95% CI: 1.25-4.32, P = 0.008).
Long-term survival rates after diabetic vitrectomy in Australia are similar to rates reported in other populations. Indigenous ethnicity and chronic renal failure were the most significant factors associated with long-term mortality. This information can guide allocation of future resources to improve the prognosis of these high risk groups.
接受糖尿病性视网膜病变（DR）玻璃体切除术的患者的 5 年生存率为 68%至 95%。尚未在澳大利亚人群中进行过研究。
我们旨在确定澳大利亚人群中接受糖尿病性玻璃体切除术的患者的生存率。
回顾性审计，三级中心医院和私人诊所。
2007 年 1 月 1 日至 2011 年 12 月 31 日期间，在南澳大利亚州和北领地首次接受糖尿病并发症玻璃体切除术的所有个人。
以前已完成了对所有合格参与者的审核。截至 2018 年 7 月 6 日的生存状况和死亡原因已通过南澳大利亚/北领地数据链接获得。使用 Kaplan-Meier 生存曲线和多变量 Cox 回归分析了生存率并确定了死亡率的危险因素。
5 年、7 年和 9 年生存率。
5 年、7 年和 9 年的生存率分别为 84.4%、77.9%和 74.7%。最常见的死亡原因是心血管疾病。与年龄无关，与死亡率增加相关的因素包括土著民族（HR=2.04，95%置信区间[CI]：1.17-3.57，P=0.012），慢性肾功能衰竭（HR=1.76，95% CI：1.07-2.89，P=0.026）和需要透析的肾衰竭（HR=2.32，95% CI：1.25-4.32，P=0.008）。
澳大利亚糖尿病玻璃体切除术后的长期生存率与其他人群报道的生存率相似。土著民族和慢性肾功能衰竭是与长期死亡率最相关的最重要因素。这些信息可以指导未来资源的分配，以改善这些高风险人群的预后。
